Tecentriq Hybreza 1875 mg/15mL
atezolizumab and hyaluronidase-tqjs · INJECTION · Genentech, Inc.
Tecentriq Hybreza is a injection containing atezolizumab and hyaluronidase-tqjs at 1875 mg/15mL, taken subcutaneous. Manufactured by Genentech, Inc..
Key Facts
- Brand Name
- Tecentriq Hybreza
- Generic Name
- atezolizumab and hyaluronidase-tqjs
- NDC Code (Product)
50242-933- Manufacturer
- Genentech, Inc.
- Strength
- 1875 mg/15mL
- Dosage Form
- INJECTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761347
- Drug Class
- Programmed Death Receptor-1 Blocking Antibody [EPC]; Endoglycosidase [EPC]
- Marketing Start
- 09/12/2024
Recall History
No Recall HistoryFrequently Asked Questions
What is Tecentriq Hybreza used for?
Tecentriq Hybreza contains atezolizumab and hyaluronidase-tqjs. It is a injection taken subcutaneous. Consult your doctor for specific uses.
Is Tecentriq Hybreza a controlled substance?
Tecentriq Hybreza is not classified as a controlled substance by the DEA.
What is the generic name for Tecentriq Hybreza?
The generic name for Tecentriq Hybreza is atezolizumab and hyaluronidase-tqjs. There are no other listed brand versions of atezolizumab and hyaluronidase-tqjs.
What is the NDC code for Tecentriq Hybreza 1875 mg/15mL?
The NDC (National Drug Code) for Tecentriq Hybreza 1875 mg/15mL is 50242-933, listed by Genentech, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)